CORRECTION article

Front. Immunol., 18 December 2023

Sec. Immunological Tolerance and Regulation

Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1352525

Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity

  • 1. Interdisciplinary Center for Clinical Research Laboratory, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

  • 2. Graduate School of Life Sciences, Würzburg University, Würzburg, Germany

  • 3. Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

  • 4. Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt

  • 5. Department of Nephropathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Article metrics

View details

1,4k

Views

570

Downloads

Incorrect Affiliation

In the published article, there was an error in affiliation “4”. Instead of “Department of Microbial Biotechnology, Institute of Biotechnology, Giza, Egypt”, it should be “Department of Microbial Biotechnology, Institute of Biotechnology, National Research Center, Giza, Egypt”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

agonist, GvHD, regulatory T cells, serum retention, TNF, TNFR2

Citation

Gamboa Vargas J, Wagner J, Shaikh H, Lang I, Medler J, Anany M, Steinfatt T, Peña Mosca J, Haack S, Dahlhoff J, Büttner-Herold M, Graf C, Viera EA, Einsele H, Wajant H and Beilhack A (2023) Corrigendum: A TNFR2-specific TNF fusion protein with improved in vivo activity. Front. Immunol. 14:1352525. doi: 10.3389/fimmu.2023.1352525

Received

08 December 2023

Accepted

12 December 2023

Published

18 December 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

14 - 2023

Updates

Copyright

*Correspondence: Harald Wajant,

†These authors have contributed equally to this work

‡These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics